Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aura Biosciences, Inc. - Common Stock (NQ:AURA)

5.350 +0.120 (+2.29%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aura Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Why United Airlines Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
Via Benzinga
US Stocks Likely To Open Mixed: 'Expect Volatility. Buckle Up,' Says Expert
U.S. stock futures were swinging between gains and losses on Thursday after snapping a three-day winning streak on Wednesday. Futures of major benchmark indices were mixed in premarket trading. Aiming... 
Via Benzinga
Topics Supply Chain World Trade
Exposures Supply Chain Tariff
Why Greenland Technologies Shares Are Trading Higher By Around 89%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Recap: Aura Biosciences Q4 Earnings
Via Benzinga
Why Check-Cap Shares Are Trading Higher By Over 52%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Aura Biosciences' Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade Disease
Aura Biosciences released early Phase 1 trial data on bel-sar for non-muscle-invasive bladder cancer, showing promising clinical activity and a favorable safety profile. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
3 Small-Cap Stocks Ready to Deliver Significant Growth
Small-cap firms will have an easier time borrowing money for growth in a lower-interest-rate environment; these are a few companies poised for a breakout. 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Aura Biosciences Touts Promising Data From Eye Cancer Candidate
Aura Biosciences announced promising Phase 2 results for bel-sar in treating melanoma, achieving 80% tumor control. 
Via Benzinga
AURA Stock Earnings: Aura Biosciences Beats EPS for Q2 2024
AURA stock results show that Aura Biosciences beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
AURA Stock Earnings: Aura Biosciences Beats EPS for Q1 2024
AURA stock results show that Aura Biosciences beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
AURA Stock Earnings: Aura Biosciences Beats EPS for Q4 2023
AURA stock results show that Aura Biosciences beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
From Aura Biosciences, Inc.
Via Business Wire
Aura Biosciences to Participate in Upcoming Investor Conferences
From Aura Biosciences Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma
From Aura Biosciences Inc.
Via Business Wire
Over $13M Bet On This Energy Stock? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed lower on Thursday, there were a few notable insider trades. 
Via Benzinga
Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
From Aura Biosciences, Inc.
Via Business Wire
Aura Biosciences to Participate in Upcoming Investor Conferences
From Aura Biosciences Inc.
Via Business Wire
Why Aura Biosciences Stock Hit A New 52-Week Low Today
Aura Biosciences Inc (NASDAQ: AURA) shares are trading lower by 34.7% to $7.18 Tuesday afternoon after the company announced pricing of its public offering of common st 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry. 
Via Benzinga
Why Alteryx Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares surged 120.8% to $0.6450 in pre-market trading after the company reported a new strategic collaboration with Celest Therapeutics for the clinical... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time for another dive into the biggest pre-market stock movers as we break down all of the latest news for Tuesday morning. 
Via InvestorPlace
Sanmina, Adtran, Ameresco And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures traded lower this morning on Tuesday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Aura Biosciences Announces Pricing of Public Offering of Common Stock
From Aura Biosciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Aura Biosciences Announces Proposed Public Offering of Common Stock
From Aura Biosciences, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.